1. Lause, M., Kamboj, A., Fernandez Faith, E. Dermatologic manifestations of endocrine disorders. Transl Pediatr. 2017;6(4):300-312.doi:10.21037/tp.2017.09.08 29184811
Google Scholar | Crossref | Medline2. Giménez García, RM., Carrasco Molina, S. Drug-Induced hyperpigmentation: review and case series. J Am Board Fam Med. 2019;32(4):628-638.doi:10.3122/jabfm.2019.04.180212 31300585
Google Scholar | Crossref | Medline3. Chaowattanapanit, S., Silpa-Archa, N., Kohli, I., Lim, HW., Hamzavi, I. Postinflammatory hyperpigmentation: a comprehensive overview: treatment options and prevention. J Am Acad Dermatol. 2017;77(4):607-621.doi:10.1016/j.jaad.2017.01.036 28917452
Google Scholar | Crossref | Medline4. Villarama, CD., Maibach, HI. Glutathione as a depigmenting agent: an overview. Int J Cosmet Sci. 2005;27(3):147-153.doi:10.1111/j.1467-2494.2005.00235.x 18492181
Google Scholar | Crossref | Medline5. Malathi, M., Thappa, DM. Systemic skin whitening/lightening agents: what is the evidence? Indian J Dermatol Venereol Leprol. 2013;79(6):842-846.doi:10.4103/0378-6323.120752 24177629
Google Scholar | Crossref | Medline6. Sonthalia, S., Daulatabad, D., Sarkar, R. Glutathione as a skin whitening agent: facts, myths, evidence and controversies. Indian J Dermatol Venereol Leprol. 2016;82(3):262-272.doi:10.4103/0378-6323.179088 27088927
Google Scholar | Crossref | Medline7. Arjinpathana, N., Asawanonda, P. Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study. J Dermatolog Treat. 2012;23(2):97-102.doi:10.3109/09546631003801619 20524875
Google Scholar | Crossref | Medline8. Weschawalit, S., Thongthip, S., Phutrakool, P., Asawanonda, P. Glutathione and its antiaging and antimelanogenic effects. Clin Cosmet Investig Dermatol. 2017;10:147-153.doi:10.2147/CCID.S128339 28490897
Google Scholar | Crossref | Medline9. Witschi, A., Reddy, S., Stofer, B., Lauterburg, BH. The systemic availability of oral glutathione. Eur J Clin Pharmacol. 1992;43(6):667-669.doi:10.1007/BF02284971 1362956
Google Scholar | Crossref | Medline10. Richie, JP., Nichenametla, S., Neidig, W et al. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. Eur J Nutr. 2015;54(2):251-263.doi:10.1007/s00394-014-0706-z 24791752
Google Scholar | Crossref | Medline11. Handog, EB., Datuin, MSL., Singzon, IA. An open-label, single-arm trial of the safety and efficacy of a novel preparation of glutathione as a skin-lightening agent in Filipino women. Int J Dermatol. 2016;55(2):153-157.doi:10.1111/ijd.12999 26148180
Google Scholar | Crossref | Medline12. Byeon, JC., Lee, S-E., Kim, T-H et al. Design of novel proliposome formulation for antioxidant peptide, glutathione with enhanced oral bioavailability and stability. Drug Deliv. 2019;26(1):216-225.doi:10.1080/10717544.2018.1551441 30843439
Google Scholar | Crossref | Medline13. Nagaraju, D., Bhattacharjee, R., Vinay, K., Saikia, UN., Parsad, D., Kumaran, MS. Efficacy of oral tranexemic acid in refractory melasma: a clinico-immuno-histopathological study. Dermatol Ther. 2018;31(5):e12704. doi:10.1111/dth.12704 30253023
Google Scholar | Crossref | Medline14. Bala, HR., Lee, S., Wong, C., Pandya, AG., Rodrigues, M. Oral tranexamic acid for the treatment of Melasma: a review. Dermatol Surg. 2018;44(6):814-825.doi:10.1097/DSS.0000000000001518 29677015
Google Scholar | Crossref | Medline15. Li, Y., Sun, Q., He, Z., Fu, L., He, C., Yan, Y. Treatment of melasma with oral administration of compound tranexamic acid: a preliminary clinical trial. J Eur Acad Dermatol Venereol. 2014;28(3):393-394.doi:10.1111/jdv.12209 23848176
Google Scholar | Crossref | Medline16. Wu, S., Shi, H., Wu, H et al. Treatment of melasma with oral administration of tranexamic acid. Aesthetic Plast Surg. 2012;36(4):964-970.doi:10.1007/s00266-012-9899-9 22552446
Google Scholar | Crossref | Medline17. Lee, HC., Thng, TGS., Goh, CL. Oral tranexamic acid (TA) in the treatment of melasma: a retrospective analysis. J Am Acad Dermatol. 2016;75(2):385-392.doi:10.1016/j.jaad.2016.03.001 27206758
Google Scholar | Crossref | Medline18. Tan, AWM., Sen, P., Chua, SH., Goh, BK. Oral tranexamic acid lightens refractory melasma. Australas J Dermatol. 2017;58(3):e105-e108.doi:10.1111/ajd.12474 27173008
Google Scholar | Crossref | Medline19. Del Rosario, E., Florez-Pollack, S., Zapata, L et al. Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma. J Am Acad Dermatol. 2018;78(2):363-369.doi:10.1016/j.jaad.2017.09.053 28987494
Google Scholar | Crossref | Medline20. Padhi, T., Pradhan, S. Oral tranexamic acid with fluocinolone-based triple combination cream versus fluocinolone-based triple combination cream alone in melasma: an open labeled randomized comparative trial. Indian J Dermatol. 2015;60(5):520. doi:10.4103/0019-5154.164416 26538719
Google Scholar | Crossref | Medline21. Na, JI., Choi, SY., Yang, SH., Choi, HR., Kang, HY., Park, K-C. Effect of tranexamic acid on melasma: a clinical trial with histological evaluation. J Eur Acad Dermatol Venereol. 2013;27(8):1035-1039.doi:10.1111/j.1468-3083.2012.04464.x 22329442
Google Scholar | Crossref | Medline22. Shihab, N., Prihartono, J., Tovar-Garza, A., Agustin, T., Legiawati, L., Pandya, AG. Randomised, controlled, double-blind study of combination therapy of oral tranexamic acid and topical hydroquinone in the treatment of melasma. Australas J Dermatol. 2020;61(3):237-242.doi:10.1111/ajd.13267 32109318
Google Scholar | Crossref | Medline23. Karn, D., Kc, S., Amatya, A., Razouria, EA., Timalsina, M. Oral tranexamic acid for the treatment of melasma. Kathmandu Univ Med J. 2012;10(4):40-43.doi:10.3126/kumj.v10i4.10993 23575051
Google Scholar | Crossref | Medline24. Shin, JU., Park, J., Oh, SH., Lee, JH. Oral tranexamic acid enhances the efficacy of low-fluence 1064-nm quality-switched neodymium-doped yttrium aluminum garnet laser treatment for melasma in Koreans: a randomized, prospective trial. Dermatol Surg. 2013;39(3 Pt 1):435-442.doi:10.1111/dsu.12060 23278870
Google Scholar | Crossref | Medline25. Cho, HH., Choi, M., Cho, S., Lee, JH. Role of oral tranexamic acid in melasma patients treated with IPL and low fluence QS Nd:YAG laser. J Dermatolog Treat. 2013;24(4):292-296.doi:10.3109/09546634.2011.643220 22103770
Google Scholar | Crossref | Medline26. Kwon, HH., Ohn, J., Suh, DH et al. A pilot study for triple combination therapy with a low-fluence 1064 nm Q-switched Nd:YAG laser, hydroquinone cream and oral tranexamic acid for recalcitrant Riehl’s Melanosis. J Dermatolog Treat. 2017;28(2):155-159.doi:10.1080/09546634.2016.1187706 27346606
Google Scholar | Crossref | Medline27. Leminen, H., Hurskainen, R. Tranexamic acid for the treatment of heavy menstrual bleeding: efficacy and safety. Int J Womens Health. 2012;4:413-421.doi:10.2147/IJWH.S13840 22956886
Google Scholar | Medline28. Berntorp, E., Follrud, C., Lethagen, S. No increased risk of venous thrombosis in women taking tranexamic acid. Thromb Haemost. 2001;86(2):714-715.11522029
Google Scholar | Medline | ISI29. Poeran, J., Rasul, R., Suzuki, S et al. Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety. BMJ. 2014;349:g4829. doi:10.1136/bmj.g4829 25116268
Google Scholar | Crossref | Medline30. Henry, DA., Carless, PA., Moxey, AJ et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2011;1:CD001886.
Google Scholar31. Sundström, A., Seaman, H., Kieler, H., Alfredsson, L. The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the general practice research database. BJOG. 2009;116(1):91-97.doi:10.1111/j.1471-0528.2008.01926.x 19016686
Google Scholar | Crossref | Medline32. Zhu, C-Y., Li, Y., Sun, Q-N., Takada, A., Kawada, A. Analysis of the effect of different doses of oral tranexamic acid on melasma: a multicentre prospective study. Eur J Dermatol. 2019;29(1):55-58.doi:10.1684/ejd.2018.3494 30734717
Google Scholar | Medline33. Debelo, H., Novotny, JA., Ferruzzi, MG. Vitamin A. Adv Nutr. 2017;8(6):992-994.doi:10.3945/an.116.014720 29141980
Google Scholar | Crossref | Medline34. Gerber, PA., Kukova, G., Bölke, E., Homey, B., Diedrichson, E. Severe hyperpigmentation and scarring following glycolic acid peel treatment in combination with low-dose isotretinoin. Eur J Med Res. 2014;19(1):60. doi:10.1186/s40001-014-0060-x 25376482
Google Scholar | Crossref | Medline35. Requena Caballero, C., Nagore, E., Sanmartín, O., Botella-Estrada, R., Serra, C., Guillén, C. Vesiculous prurigo pigmentosa in a 13-year-old girl: good response to isotretinoin. J Eur Acad Dermatol Venereol. 2005;19(4):474-476.doi:10.1111/j.1468-3083.2005.01179.x 15987297
Google Scholar | Crossref | Medline36. Akoglu, G., Boztepe, G., Karaduman, A. Prurigo pigmentosa successfully treated with low-dose isotretinoin. Dermatology. 2006;213(4):331-333.doi:10.1159/000096197 17135740
Google Scholar | Crossref | Medline37. Wang, F., Zhao, Y-K., Wang, Z., Liu, J-H., Luo, D-Q. Erythema Dyschromicum perstans response to isotretinoin. JAMA Dermatol. 2016;152(7):841-842.doi:10.1001/jamadermatol.2015.6185 26933923
Google Scholar | Crossref | Medline38. Winhoven, SM., Ahmed, I., Owen, CM., Lear, JT. Postinflammatory hyperpigmentation in an Asian patient: a dramatic response to oral isotretinoin (13-cis-retinoic acid). Br J Dermatol. 2005;152(2):368-369.doi:10.1111/j.1365-2133.2005.06286.x 15727656
Google Scholar | Crossref | Medline39. Swineford, SL., Drucker, CR. Palliative treatment of paraneoplastic acanthosis nigricans and oral florid papillomatosis with retinoids. J Drugs Dermatol. 2010;9(9):1151-1153.20865850
Google Scholar | Medline40. Maurelli, M., Gisondi, P., Girolomoni, G. Kyrle’s disease effectively treated with oral isotretinoin. J Dermatolog Treat. 2018;29(6):630-632.doi:10.1080/09546634.2017.1422080 29285959
Google Scholar | Crossref | Medline41. Muthu, SK., Narang, T., Saikia, UN., Kanwar, AJ., Parsad, D., Dogra, S. Low-Dose oral isotretinoin therapy in lichen planus pigmentosus: an open-label non-randomized prospective pilot study. Int J Dermatol. 2016;55(9):1048-1054.doi:10.1111/ijd.13293 27062273
Google Scholar | Crossref | Medline42. Hernandez-Perez, E., Khawaja, HA., Alvarez, TY. Oral isotretinoin as part of the treatment of cutaneous aging. Dermatol Surg. 2000;26(7):649-652.doi:10.1046/j.1524-4725.2000.99210.x 10886272
Google Scholar | Crossref | Medline43. Levy, LL., Zeichner, JA. Management of acne scarring, part II: a comparative review of non-laser-based, minimally invasive approaches. Am J Clin Dermatol. 2012;13(5):331-340.doi:10.2165/11631410-000000000-00000 22849351
Google Scholar | Crossref | Medline44. Zi, S-X., Ma, H-J., Li, Y et al. Oligomeric proanthocyanidins from grape seeds effectively inhibit ultraviolet-induced melanogenesis of human melanocytes in vitro. Int J Mol Med. 2009;23(2):197-204.19148543
Google Scholar | Medline45. Yamakoshi, J., Sano, A., Tokutake, S et al. Oral intake of proanthocyanidin-rich extract from grape seeds improves chloasma. Phytother Res. 2004;18(11):895-899.doi:10.1002/ptr.1537 15597304
Google Scholar | Cro